JPWO2020193999A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020193999A5 JPWO2020193999A5 JP2021557827A JP2021557827A JPWO2020193999A5 JP WO2020193999 A5 JPWO2020193999 A5 JP WO2020193999A5 JP 2021557827 A JP2021557827 A JP 2021557827A JP 2021557827 A JP2021557827 A JP 2021557827A JP WO2020193999 A5 JPWO2020193999 A5 JP WO2020193999A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- silicon
- composition
- nucleic acid
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (18)
少なくとも１つの脂質で表面処理され、少なくとも１つのアミノ酸でさらに処理されたケイ素ナノ粒子を含み、
前記ケイ素ナノ粒子は、少なくとも５０重量％のケイ素を含み、前記短鎖干渉ＲＮＡ又はメッセンジャーＲＮＡがロードされており、
ケイ素の核酸に対する比が２：１～８：１である、組成物。 A composition for the controlled release of a nucleic acid that is a short interfering RNA or messenger RNA, the composition comprising:
comprising silicon nanoparticles surface treated with at least one lipid and further treated with at least one amino acid;
the silicon nanoparticles contain at least 50% by weight silicon and are loaded with the short interfering RNA or messenger RNA;
A composition wherein the ratio of silicon to nucleic acid is from 2:1 to 8:1 .
請求項１に記載の組成物。A composition according to claim 1.
請求項１に記載の組成物。 The ratio of silicon to nucleic acid is between 2:1 and 3:1.
A composition according to claim 1 .
請求項１に記載の組成物。 further comprising a gene transfer reagent and/or further comprising at least one disaccharide;
A composition according to claim 1.
請求項４に記載の組成物。 the gene transfer reagent is Lipofectamine;
The composition according to claim 4 .
請求項１～５のいずれか１項に記載の組成物。 The ratio of lipid to silicon is from 1:1 to 15:1 , and/or the ratio of amino acids to silicon is from 0.05:1 to 2:1.
The composition according to any one of claims 1 to 5 .
請求項１～５のいずれか１項に記載の組成物。 The silicon nanoparticles have an average diameter of 20 to 200 nm.
The composition according to any one of claims 1 to 5.
請求項１～５のいずれか１項に記載の組成物。 The at least one lipid may include phosphatidylcholine, hydrogenated phosphatidylcholine , didecanoylphosphatidylcholine, mirystoyl phosphatidylcholine, lecithin, phosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, cholesteryl N-( 2-dimethylaminoethyl) carbamate, stearylamine, or a combination thereof;
The composition according to any one of claims 1 to 5 .
請求項１～５のいずれか１項に記載の組成物。 The at least one lipid is phosphatidylcholine, hydrogenated phosphatidylcholine , lecithin , phosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, cholesteryl N-(2-dimethylaminoethyl)carbamate, stearylamine. , or a combination thereof;
The composition according to any one of claims 1 to 5 .
請求項１～５のいずれか１項に記載の組成物。 the at least one amino acid is selected from arginine, glycine, histidine, or a combination thereof;
The composition according to any one of claims 1 to 5 .
前記組成物は、少なくとも１つの脂質で表面処理され、少なくとも１つのアミノ酸でさらに処理されたケイ素ナノ粒子を含み、The composition comprises silicon nanoparticles surface treated with at least one lipid and further treated with at least one amino acid;
前記ケイ素ナノ粒子は、少なくとも５０重量％のケイ素を含むと共に、前記短鎖干渉ＲＮＡ又はメッセンジャーＲＮＡがロードされており、the silicon nanoparticles contain at least 50% by weight silicon and are loaded with the short interfering RNA or messenger RNA;
ケイ素の核酸に対する比が２：１～８：１である、使用。Use in which the ratio of silicon to nucleic acid is between 2:1 and 8:1.
請求項１～１０のいずれか１項に記載の組成物の使用。 In the manufacture of drugs for use in the treatment of eye disorders,
Use of a composition according to any one of claims 1 to 10 .
請求項１～１０のいずれか１項に記載の組成物の使用。 In the manufacture of drugs for delivery to the eye,
Use of a composition according to any one of claims 1 to 10 .
請求項１～１０のいずれか１項に記載の使用。 In the manufacture of drugs for the treatment of ocular tissues,
Use according to any one of claims 1 to 10 .
請求項１４に記載の使用。 the ocular tissue is selected from the cornea, sclera, iris, ciliary body, choroid, zonular fibers, lens capsule, lens nucleus, vitreous, and retina;
Use according to claim 14 .
請求項１～１０のいずれか１項に記載の組成物の使用。 In the manufacture of drugs for the treatment of disorders of the eye,
Use of a composition according to any one of claims 1 to 10 .
請求項１６に記載の使用。 The ocular disorder is selected from macular degeneration, conjunctivitis, glaucoma, diabetic retinopathy, diabetic macular edema, keratoconus, cataract, retinitis, or uveitis.
Use according to claim 16 .
請求項１７に記載の使用。Use according to claim 17.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1904337.1A GB201904337D0 (en) | 2019-03-28 | 2019-03-28 | A delivery system |
| GB1904337.1 | 2019-03-28 | ||
| PCT/GB2020/050854 WO2020193999A1 (en) | 2019-03-28 | 2020-03-30 | A delivery system comprising silicon nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529579A JP2022529579A (en) | 2022-06-23 |
| JPWO2020193999A5 true JPWO2020193999A5 (en) | 2023-10-30 |
Family
ID=66442849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557827A Pending JP2022529579A (en) | 2019-03-28 | 2020-03-30 | Delivery system containing silicon nanoparticles |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230052784A1 (en) |
| EP (1) | EP3946280A1 (en) |
| JP (1) | JP2022529579A (en) |
| CN (2) | CN113677332B (en) |
| AU (1) | AU2020249810A1 (en) |
| CA (1) | CA3133117C (en) |
| GB (1) | GB201904337D0 (en) |
| WO (1) | WO2020193999A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202110645D0 (en) * | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Protection of biological molecules from degradation |
| GB202110646D0 (en) * | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Nucleic acid vector compositions |
| GB202110644D0 (en) * | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Improved nucleic acid vector particles |
| GB202210794D0 (en) | 2022-07-22 | 2022-09-07 | Sisaf Ltd | Lipid formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208556A1 (en) * | 2004-10-29 | 2009-08-20 | Regents Of The University Of California, The | Porous photonic crystals for drug delivery to the eye |
| IT1394656B1 (en) | 2009-07-03 | 2012-07-05 | Brev Angela Srl | PROCESS FOR THE PRODUCTION AND ASSEMBLY OF A SYRINGE FOR MEDICAL OPERATIONS |
| GB0913255D0 (en) * | 2009-07-30 | 2009-09-02 | Sisaf Ltd | Topical composition |
| SG11201401499XA (en) * | 2011-10-14 | 2014-09-26 | Stc Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| EP2946793A1 (en) * | 2014-05-23 | 2015-11-25 | Universitat Rovira I Virgili | Silicon particles targeting tumor cells |
| AU2016291224B2 (en) * | 2015-07-09 | 2021-12-23 | The Regents Of The University Of California | Fusogenic liposome-coated porous silicon nanoparticles |
| WO2017040976A1 (en) * | 2015-09-02 | 2017-03-09 | Erkki Ruoslahti | Compounds and compositions for targeting brain injuries and methods of use thereof |
| WO2017181115A1 (en) * | 2016-04-14 | 2017-10-19 | Spinnaker Biosciences, Inc. | Porous silicon materials comprising a metal silicate for delivery of therapeutic agents |
-
2019
- 2019-03-28 GB GBGB1904337.1A patent/GB201904337D0/en not_active Ceased
-
2020
- 2020-03-30 US US17/598,703 patent/US20230052784A1/en active Pending
- 2020-03-30 AU AU2020249810A patent/AU2020249810A1/en active Pending
- 2020-03-30 CA CA3133117A patent/CA3133117C/en active Active
- 2020-03-30 CN CN202080025724.5A patent/CN113677332B/en active Active
- 2020-03-30 EP EP20718725.3A patent/EP3946280A1/en active Pending
- 2020-03-30 WO PCT/GB2020/050854 patent/WO2020193999A1/en unknown
- 2020-03-30 CN CN202311342050.3A patent/CN117398362A/en active Pending
- 2020-03-30 JP JP2021557827A patent/JP2022529579A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gote et al. | Ocular drug delivery: present innovations and future challenges | |
| Yadav et al. | Glaucoma: Current treatment and impact of advanced drug delivery systems | |
| Maulvi et al. | Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration | |
| JP7026507B2 (en) | Methods and Biocompatible Compositions to Achieve Sustained Release of Drugs in the Eye | |
| JP2017061467A5 (en) | ||
| EP2309980A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| KR20060082792A (en) | Ophthalmic drug delivery device | |
| US20170157038A1 (en) | Ophthalmic drug delivery method | |
| Tawfik et al. | Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy | |
| Shivhare et al. | An update review on novel advanced ocular drug delivery system | |
| Vishal et al. | Current status and advanced approaches in ocular drug delivery system | |
| Raj et al. | Ocular drug delivery system: challenges and approaches | |
| Pignatello et al. | Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity | |
| Zhang et al. | Intractable ocular diseases and treatment progress | |
| Lee et al. | Ophthalmic dosage forms for drug delivery to posterior segment | |
| JPWO2020193999A5 (en) | ||
| Hajare et al. | A Rational Approach to Ocular Drug Delivery System: An Overview | |
| Amrutkar et al. | Nanocarriers for ocular drug delivery: Recent advances and future opportunities | |
| Mythili et al. | Ocular drug delivery system-an update review | |
| Herrero-Vanrell et al. | Ocular pharmacokinetic drug, bioavailability and intraocular drug delivery systems | |
| Bennett | Topical versus systemic ocular drug delivery | |
| Arora et al. | Ophthalmic Drug Delivery System-A Concise Review on its Conventional and Novel Approaches | |
| Dave et al. | Advancement and tribulations in ocular drug delivery | |
| Mello-Filho et al. | Helical intravitreal triamcinolone acetonide implant: a 6-month surgical feasibility study in rabbits | |
| Shifali et al. | Recent trends in Ocular Drug Delivery System: A Review |